AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 16.25 |
Market Cap | 1.95B |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -1.81 |
PE Ratio (ttm) | -9.38 |
Forward PE | n/a |
Analyst | Buy |
Ask | 16.7 |
Volume | 1,264,014 |
Avg. Volume (20D) | 389,067 |
Open | 16.19 |
Previous Close | 17.18 |
Day's Range | 15.70 - 17.67 |
52-Week Range | 1.61 - 22.00 |
Beta | undefined |
About MESO
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines in the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchyma...
Analyst Forecast
According to 4 analyst ratings, the average rating for MESO stock is "Buy." The 12-month stock price forecast is $13.5, which is a decrease of -20.49% from the latest price.